Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on Oxurion NV. We currently have 0 research reports from 1 professional analysts.
Date | Source | Announcement |
---|---|---|
06Sep18 16:40 | GNW | ThromboGenics Business Update - H1 2018 |
03Sep18 16:40 | GNW | ThromboGenics becomes "Oxurion" |
19Jul18 16:40 | GNW | ThromboGenics Reports Day 150 Topline Data from its Phase 1/2 Clinical Study evaluating THR-317 (anti-PlGF) for the Treatment of Diabetic Macular Edema (DME) |
27Jun18 06:30 | GNW | ThromboGenics Plans Name Change to "Oxurion" |
21Jun18 07:00 | GNW | ThromboGenics Partners with Prevent Blindness at 2018 Focus on Eye Health National Summit in Washington DC |
25May18 06:30 | GNW | ThromboGenics Enrolls First Patient in Phase 1 Clinical Study Evaluating THR-149, a plasma kallikrein inhibitor, for treatment of Diabetic Macular Edema (DME) |
23May18 07:00 | GNW | ThromboGenics to present a preclinical overview of its two most advanced diabetic eye disease clinical candidates, THR-317 and THR-149, at EASDec 2018 |
Share: